{
  "content": "Conclusions\nAmiodarone use was associated with significantly increased stroke and systemic embolism risk and a lower time in the therapeutic range when used with warfarin. Apixaban consistently reduced the rate of stroke and systemic embolism, death, and major bleeding compared with warfarin in amiodarone-treated patients and patients who were not on amiodarone.",
  "source": "https://www.sciencedirect.com/science/article/pii/S0735109714057982",
  "chunk_id": "959ec5c0-0371-429c-af2c-6da0967c4d99",
  "similarity_score": 0.28877997398376465,
  "query": "stroke prevention atrial fibrillation amiodarone beta-blockers thromboembolic events anticoagulation",
  "rank": 36,
  "title": "Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: Insights from the ARISTOTLE trial",
  "authors": "Greg Flaker, Renato D. Lopes, Elaine Hylek, Daniel M. Wojdyla, Laine Thomas, Sana M. Al-Khatib, Renee M. Sullivan, Stefan H. Hohnloser, David Garcia, Michael Hanna, John Amerena, Veli-Pekka Harjola, Paul Dorian, Alvaro Avezum, Matyas Keltai, Lars Wallentin, Christopher B. Granger, ARISTOTLE Committees and Investigators",
  "year": "2014",
  "journal": "Journal of the American College of Cardiology",
  "reference": "Flaker, G., Lopes, R. D., Hylek, E., Wojdyla, D. M., Thomas, L., Al-Khatib, S. M., Sullivan, R. M., Hohnloser, S. H., Garcia, D., Hanna, M., Amerena, J., Harjola, V.-P., Dorian, P., Avezum, A., Keltai, M., Wallentin, L., Granger, C. B., & ARISTOTLE Committees and Investigators. (2014). Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: Insights from the ARISTOTLE trial. Journal of the American College of Cardiology, 64(15), 1541-1550. https://doi.org/10.1016/j.jacc.2014.07.984",
  "doi": "10.1016/j.jacc.2014.07.984",
  "chunk_index": 6,
  "total_chunks": 102,
  "retrieved_at": "2025-07-24T22:33:38.168736"
}